Edition:
United Kingdom

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

1.97USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
234,102
52-wk High
$3.14
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

Geron Corp Q2 loss per share $0.05
Wednesday, 3 Aug 2016 

Geron Corp : Q2 loss per share $0.05 . Q2 revenue $211,000 . Geron corporation reports second quarter 2016 financial results and recent events . Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q2 revenue view $302,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes

* Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes Source text for Eikon: Further company coverage: